Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ibio Inc (NYSE MKT LLC:IBIO)

0.71
Delayed Data
As of 1:30pm ET
 0.00 / 0.00%
Today’s Change
0.40
Today|||52-Week Range
3.48
+3.65%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$54.5M

Company Description

iBio, Inc. is a biotechnology company which focuses on commercializing its proprietary technology, iBioLaunch and iBioModulator, and developing product candidates derived from these platforms. iBioLaunch is a proprietary, transformative platform technology for development and production of biologics using transient gene expression in hydroponically grown, unmodified green plants. iBioModulator is a proprietary technology platform that is designed to improve the potency and duration of effect of both prophylactic and therapeutic vaccines produced with any recombinant expression technology including iBioLaunch. The company was founded on April 15, 1993 and is headquartered in Newark, DE.

Contact Information

iBio, Inc.
9 Innovation Way
Newark Delaware 19711
P:(302) 355-0650
Investor Relations:

Employees

Shareholders

Other institutional29.37%
Individual stakeholders24.32%
Mutual fund holders2.78%

Top Executives

Robert B. KayExecutive Chairman & Chief Executive Officer
Robert L. ErwinPresident
Mark GiannoneChief Financial Officer
Terence E. RyanChief Scientific Officer
Douglas C. HicksVice President-Business Development